This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Vertex Plunges Around 24% in Six Months: How to Play the Stock
by Kinjel Shah
Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.
VRTXPositive Net Change MRNANegative Net Change CRSPPositive Net Change
biotechs pharmaceuticals
Top Research Reports for Alphabet, IBM & Merck
by Mark Vickery
Alphabet, IBM, and Merck headline Zacks' latest research reports, with insights spanning AI, cloud growth, and pipeline challenges.
IBMPositive Net Change MRKPositive Net Change MUPositive Net Change MFCPositive Net Change SDPositive Net Change GOOGLPositive Net Change CFGPositive Net Change NRXSPositive Net Change
computers internet medical oil-energy pharmaceuticals
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
by Sundeep Ganoria
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer
by Zacks Equity Research
Merck and Daiichi's raludotatug deruxtecan wins FDA Breakthrough tag for treating CDH6 expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?
by Kinjel Shah
GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.
GSKPositive Net Change PFEPositive Net Change MRNANegative Net Change
pharmaceuticals
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?
by Kinjel Shah
AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.
NVONegative Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
by Zacks Equity Research
GLUE surges 44% after sealing a $5.7B licensing deal with NVS to advance molecular glue degraders for immune diseases.
NVSPositive Net Change RHHBYNegative Net Change GLUEPositive Net Change
biotechs medical pharmaceuticals
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
by Ahan Chakraborty
Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Under $20 Breakout Trio Investors Shouldn't Ignore
by Tirthankar Chakraborty
Sally Beauty, Broadstone Net Lease and Opus Genetics emerge as today's breakout stock picks under $20, flagged for potential near-term gains.
SBHPositive Net Change BNLPositive Net Change IRDPositive Net Change
pharmaceuticals reit retail ride-hailing
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
by Kinjel Shah
Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
pharmaceuticals
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
by Ahan Chakraborty
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
PFEPositive Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
by Zacks Equity Research
Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.
REGNPositive Net Change SNYPositive Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
by Zacks Equity Research
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
ZTSPositive Net Change CRMDPositive Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
by Sundeep Ganoria
MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.
PFEPositive Net Change MRNANegative Net Change NVAXPositive Net Change BNTXNo Net Change
biotechs medical pharmaceuticals vaccines
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
by Zacks Equity Research
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
JNJPositive Net Change ANIPNegative Net Change CRMDPositive Net Change PTGXPositive Net Change
pharmaceuticals
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
by Zacks Equity Research
Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.
CRMDPositive Net Change KNSAPositive Net Change PHARNegative Net Change RAPPPositive Net Change
biotechnology biotechs medical pharmaceuticals
OLMA Stock Soars 47% in September So Far on Second PFE Deal
by Zacks Equity Research
Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.
AZNPositive Net Change NVSPositive Net Change PFEPositive Net Change OLMAPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects
by Kinjel Shah
Pfizer's late-stage pipeline, from oncology blockbusters to mRNA vaccines, positions it for long-term growth despite recent setbacks.
AZNPositive Net Change BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock
by Sundeep Ganoria
ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?
by Ekta Bagri
Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change BNTXNo Net Change
biotechnology biotechs medical pharmaceuticals
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
by Ekta Bagri
Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.
AZNPositive Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Oracle, AstraZeneca, Shopify and Blue Ridge Bankshares
by Zacks Equity Research
Oracle, AstraZeneca, Shopify, and Blue Ridge Bankshares show strong growth and strategic market opportunities.
AZNPositive Net Change ORCLNegative Net Change SHOPNegative Net Change BRBSNegative Net Change
pharmaceuticals
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
by Zacks Equity Research
Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.
SNYPositive Net Change ABBVPositive Net Change RGNXPositive Net Change FDMTNegative Net Change
biotechs medical pharmaceuticals
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
by Zacks Equity Research
Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.
CRMDPositive Net Change KNSAPositive Net Change TVTXPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?
by Kinjel Shah
Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.
MRKPositive Net Change MRNANegative Net Change SMMTPositive Net Change VRNANo Net Change
pharmaceuticals